Skip to main content
Orchid Pharma Limited logo

Orchid Pharma Limited — Investor Relations & Filings

Ticker · ORCHPHARMA ISIN · INE191A01027 LEI · 33580076KIKCYSLZVF05 BSE.NS Manufacturing
Open in API
Filings indexed 451 across all filing types
Latest filing 2022-12-30 Declaration of Voting R…
Country IN India
Listing BSE.NS ORCHPHARMA

About Orchid Pharma Limited

https://www.orchidpharma.com/

Orchid Pharma Limited is a vertically integrated organization focused on the development, manufacture, and marketing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). The company specializes in the anti-infectives segment, with a particular emphasis on cephalosporins and penicillins. Its operations span the entire value chain, including advanced research and development, process chemistry, and large-scale manufacturing. Orchid Pharma maintains facilities that adhere to rigorous international regulatory standards, enabling the supply of high-quality generic formulations and complex molecules to global markets. The company prioritizes innovation in chemical synthesis and formulation development to address complex therapeutic requirements and enhance healthcare outcomes through a robust portfolio of essential medicines.

Recent filings

Filing Released Lang Actions
Shareholders meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed report titled 'Voting Results and Scrutinizer Report of the Extraordinary General Meeting (EGM)' of Orchid Pharma Limited. It includes references to the Companies Act, 2013, SEBI Listing Regulations, and details about the voting process, vote counts, and the scrutinizer's responsibilities. The document is not an announcement of a report but the actual consolidated scrutinizer's report containing substantive voting results and analysis from the EGM held on December 29, 2022. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)', which covers official results from shareholder votes at any general meeting (AGM or EGM). Therefore, the correct classification is DVA.
2022-12-30 English
Shareholders meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled 'Proceedings of the Extraordinary General Meeting (EGM) of Orchid Pharma Limited' and details the conduct and summary of the EGM held on December 29, 2022. It includes references to the meeting agenda, attendance, voting procedures, and compliance with regulatory circulars. The document does not contain financial statements or detailed financial analysis but rather a narrative of the meeting proceedings. It also mentions that voting results and scrutinizer reports will be submitted later, indicating this document is a formal record of the meeting proceedings. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA), as it is an official record related to shareholder meeting proceedings and voting. Therefore, the appropriate classification is DVA with high confidence.
2022-12-30 English
Credit Rating
Regulatory Filings Classification · 95% confidence The document is a disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing about a revision in rating watch descriptors by CARE Ratings Limited for the company's bank facilities. It is an update on credit rating status, not a financial report, earnings release, or management discussion. The document is short (1857 characters) and serves as a regulatory announcement about credit rating changes. It does not contain financial statements or detailed analysis. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2022-12-24 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings Classification · 95% confidence The document is a short notice informing about the schedule of Analyst / Institutional Investor Meetings for Orchid Pharma Limited. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The document mentions that a copy of the presentation is available on the company's website but does not include the presentation itself. The length is only 1413 characters, indicating it is a brief announcement rather than a full report or presentation. Therefore, this document is an announcement related to investor presentations, not the presentation itself. According to the classification rules, such announcements fall under Regulatory Filings (RNS) as a general regulatory announcement and do not qualify as an Investor Presentation (IP) or Annual Report (10-K).
2022-12-15 English
Book Closure
Regulatory Filings Classification · 95% confidence The document is an official communication to stock exchanges regarding the scheduling of an Extra Ordinary General Meeting (EGM) of Orchid Pharma Limited. It references regulatory requirements under SEBI Listing Regulations and Companies Act, mentions the date and mode of the EGM, details about the register closure, cut-off date for voting, and the dispatch of the EGM notice. The document does not contain the actual EGM notice or voting results, nor does it include financial data or management discussion. It is an announcement about the upcoming EGM, not the meeting materials or results themselves. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement about the meeting scheduling and procedural details.
2022-12-12 English
Record Date
Regulatory Filings Classification · 95% confidence The document is an official communication to stock exchanges regarding the scheduling of an Extra Ordinary General Meeting (EGM) of Orchid Pharma Limited. It references regulatory requirements under SEBI Listing Regulations and Companies Act, and provides details about the meeting date, e-voting, and book closure dates. It explicitly states that the EGM Notice will be dispatched later and submitted in due course, indicating this document is an announcement or intimation about the meeting rather than the meeting materials or voting results themselves. The document length is short (2370 characters) and it does not contain any financial data, voting results, or detailed meeting materials. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement about the EGM scheduling and related procedural information, not the actual notice or voting results.
2022-12-12 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.